PD-L1 expression has been demonstrated to be an important predictive biomarker for ICI efficacy in metastatic NSCLC, while its predictive role for tumor pathologic response in the neoadjuvant setting is under evaluation. The gene discussed is CD274; the disease is non-small cell lung carcinoma.